Selling a dental practice or group in the UK

You own a UK dental practice or multi-site group worth between £5M and £50M in enterprise value. A single-site practice at the upper end of the segment. A regional group of three to twelve sites. A larger platform built over a decade or more by acquisition. NHS-heavy, private-heavy, or mixed.

The buyer pool is concentrated and unusually well-funded. 8 to 12 active corporate and PE-backed dental consolidators acquire in the UK at any given time, each with distinct strategies on NHS-vs-private mix, geography, site size, and integration intensity. Most owners we work with have been approached by at least one consolidator already. The question is rarely whether the market exists. It is whether running a real competitive process across the full pool produces a materially better outcome than working a single approach.

We engage 12 to 24 months before a target exit. The longer window matters because the highest-return preparation work in dental — addressing CQC standing where required, documenting associate retention and lock-ins, cleaning up site-level reporting, and addressing the NHS contract position — takes time to do credibly.

This is not the right fit if your practice or group sits below £5M EV, or if CQC standing is in active remediation. In both cases we will be straight about why and refer where appropriate. It is also not the right fit if you are committed to accepting a specific approach already on the table; that is a different mandate.

Buyer diligence in UK dental M&A focuses on six items. Each is fixable in advance, and each consistently drives the difference between top-of-range and median-multiple outcomes.

NHS vs private mix first. Buyers value the two streams differently. NHS UDA contract income is highly predictable but margin-controlled; private income carries higher growth optionality. Most consolidators prefer a balanced mix — typically 40-60% NHS — with a credible private-growth story. Pure NHS-only practices trade differently and to a narrower buyer pool.

CQC standing second. Outstanding or Good ratings materially affect both deal certainty and headline price. Requires Improvement is fixable but always discounts. We typically advise addressing remediable CQC issues 6 to 12 months ahead of any process so the rating is settled by the time the data room opens.

Site economics third. Per-site EBITDA, chair-time utilisation, average revenue per chair per day, patient retention, and the private-treatment uptake rate. Multi-site groups where individual site performance varies widely against the group average are valued on the weaker sites, not the stronger ones.

Associate retention and lock-in fourth. The single most commonly cited late-stage diligence concern. Buyers look at associate tenure, restrictive covenants, billings per associate, and any post-sale lock-in arrangements. Sales where key associates have not been engaged with the transaction story consistently re-trade or fall apart at completion.

UDA contract position fifth. Buyers want a clean read on the UDA contract, any open underperformance position, NHS England correspondence, and the trajectory of UDA targets relative to delivery. We help owners surface this transparently rather than have it discovered in diligence.

Goodwill and brand sixth. For mixed and private-heavy practices, the local brand, patient base, digital presence and reviewer profile materially affect valuation. Buyers will look at Google reviews, Trustpilot if relevant, and the digital marketing engine that drives new private patient acquisition.

Our six-stage process runs senior-led from first conversation to completion. For dental, three things shape execution.

Regulated diligence sits on a longer clock than commercial diligence. CQC reports, NHS contract novation, and (for larger contract transfers) NHS England engagement. We build this into the process design from the start rather than discovering the timeline late.

Buyer mapping is concentrated and granular. The active consolidators differ in strategy, size preference, NHS exposure tolerance, and integration model. Knowing which subset is deploying capital today, and on what terms, is the difference between a process that produces competitive tension and one that defaults to a single bilateral conversation. Our buyer mapping is supported by our proprietary technology layer for surfacing acquirer signals from licensed market data.

Associate engagement is structured into the process design, not bolted on at the end. Get this wrong and you risk both the deal and the team. See the healthcare services pillar for context and veterinary practices for the closest adjacent niche.